|
🐜
|
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
20 auth.
L. Dang,
D. White,
S. Gross,
Bryson D. Bennett,
M. Bittinger,
E. Driggers,
V. Fantin,
H. G. Jang,
Shengfang Jin,
M. Keenan,
...
K. Marks,
R. Prins,
P. Ward,
K. Yen,
L. Liau,
J. Rabinowitz,
L. Cantley,
C. Thompson,
M. V. Heiden,
Shinsan M. Su
|
11 |
2010 |
11
🐜
|
|
🐜
|
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
26 auth.
M. Figueroa,
O. Abdel-Wahab,
Chao Lu,
P. Ward,
Jay L. Patel,
A. Shih,
Yushan Li,
Neha Bhagwat,
A. Vasanthakumar,
H. Fernandez,
M. Tallman,
Zhuoxin Sun,
K. Wolniak,
J. Peeters,
Wei Liu,
...
S. Choe,
V. Fantin,
E. Paietta,
B. Löwenberg,
J. Licht,
L. Godley,
R. Delwel,
P. Valk,
C. Thompson,
R. Levine,
A. Melnick
|
11 |
2010 |
11
🐜
|
|
🐜
|
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
16 auth.
P. Ward,
Jay L. Patel,
David R. Wise,
O. Abdel-Wahab,
Bryson D. Bennett,
H. Coller,
J. Cross,
V. Fantin,
C. Hedvat,
A. Perl,
...
J. Rabinowitz,
M. Carroll,
Shinsan M. Su,
K. Sharp,
R. Levine,
C. Thompson
|
10 |
2010 |
10
🐜
|
|
🦁
|
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.
V. Fantin,
J. St-Pierre,
P. Leder
|
10 |
2006 |
10
🦁
|
|
🐜
|
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
13 auth.
S. Gross,
R. Cairns,
M. Minden,
E. Driggers,
M. Bittinger,
H. G. Jang,
M. Sasaki,
Shengfang Jin,
D. Schenkein,
Shinsan M. Su,
...
L. Dang,
V. Fantin,
T. Mak
|
9 |
2010 |
9
🐜
|
|
🐜
|
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
33 auth.
H. Zou,
L. Friboulet,
David P. Kodack,
Lars D. Engstrom,
Qiuhua Li,
Melissa West,
Ruth W. Tang,
Hui Wang,
Konstantinos E. Tsaparikos,
Jinwei Wang,
Sergei L. Timofeevski,
Ryohei Katayama,
D. Dinh,
Hieu Lam,
Justine L. Lam,
...
S. Yamazaki,
Wenyue Hu,
B. Patel,
Divya Bezwada,
R. Frias,
E. Lifshits,
Sidra Mahmood,
J. Gainor,
T. Affolter,
P. Lappin,
H. Gukasyan,
N. Lee,
Shibing Deng,
R. Jain,
T. Johnson,
A. Shaw,
V. Fantin,
T. Smeal
|
8 |
2015 |
8
🐜
|
|
🐜
|
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
28 auth.
R. Piazza,
S. Valletta,
N. Winkelmann,
S. Redaelli,
R. Spinelli,
A. Pirola,
L. Antolini,
L. Mologni,
C. Donadoni,
E. Papaemmanuil,
S. Schnittger,
Dong-Wook Kim,
J. Boultwood,
F. Rossi,
G. Gaipa,
...
G. D. Martini,
P. F. D. Celle,
H. G. Jang,
V. Fantin,
G. Bignell,
V. Magistroni,
T. Haferlach,
E. Pogliani,
P. Campbell,
A. Chase,
W. Tapper,
N. Cross,
C. Gambacorti-Passerini
|
8 |
2012 |
8
🐜
|
|
🐜
|
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
19 auth.
M. F. Amary,
S. Damato,
D. Halai,
M. Eskandarpour,
F. Berisha,
F. Bonar,
S. McCarthy,
V. Fantin,
K. Straley,
S. Lobo,
...
W. Aston,
Claire L. Green,
R. Gale,
R. Tirabosco,
A. Futreal,
P. Campbell,
N. Presneau,
A. Flanagan,
A. Flanagan
|
8 |
2011 |
8
🐜
|
|
🐬
|
A Novel 160-kDa Phosphotyrosine Protein in Insulin-treated Embryonic Kidney Cells Is a New Member of the Insulin Receptor Substrate Family*
B. Lavan,
V. Fantin,
E. Chang,
William Arbuthnot Sir Lane,
S. Keller,
G. Lienhard
|
8 |
1997 |
8
🐬
|
|
🐜
|
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
8 auth.
O. Andronesi,
G. S. Kim,
E. Gerstner,
T. Batchelor,
A. Tzika,
V. Fantin,
...
M. V. Vander Heiden,
A. Sorensen
|
8 |
2012 |
8
🐜
|
|
🐜
|
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
17 auth.
E. Galanis,
K. Jaeckle,
M. Maurer,
J. Reid,
M. Ames,
J. Hardwick,
J. Reilly,
A. Loboda,
M. Nebozhyn,
V. Fantin,
...
V. Richon,
B. Scheithauer,
C. Giannini,
P. Flynn,
D. Moore,
J. Zwiebel,
J. Buckner
|
8 |
2009 |
8
🐜
|
|
🐜
|
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
21 auth.
W. Pope,
R. Prins,
M. Albert Thomas,
R. Nagarajan,
K. Yen,
M. Bittinger,
N. Salamon,
A. Chou,
W. Yong,
H. Soto,
...
N. Wilson,
E. Driggers,
H. G. Jang,
Shinsan M. Su,
D. Schenkein,
A. Lai,
T. Cloughesy,
H. Kornblum,
Hong Wu,
V. Fantin,
L. Liau
|
8 |
2012 |
8
🐜
|
|
🐢
|
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
23 auth.
H. Zou,
Qiuhua Li,
Lars D. Engstrom,
Melissa West,
Vicky A. Appleman,
K. Wong,
M. McTigue,
Ya-Li Deng,
Wei Liu,
A. Brooun,
...
Sergei L. Timofeevski,
S. McDonnell,
P. Jiang,
M. D. Falk,
P. Lappin,
T. Affolter,
T. Nichols,
Wenyue Hu,
Justine L. Lam,
T. Johnson,
T. Smeal,
A. Charest,
V. Fantin
|
7 |
2015 |
7
🐢
|
